2
3
4
Other modeling considerations will be provided on the webcast.
WEBCAST INFORMATION:
Johnson & Johnson will conduct a conference call with investors to discuss this earnings release today at 8:30 a.m., Eastern Time. A simultaneous webcast of the call for investors and other interested parties may be accessed by visiting the Johnson & Johnson website. A replay and podcast will be available approximately two hours after the live webcast in the Investors section of the company s website at events-and-presentations.
ABOUT JOHNSON & JOHNSON:
At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That s why for more than 130 years, we have aimed to keep people well at every age and every stage of life. Today, as the world s largest and most broadly-based health care company, we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communiti
RAMM Pharma Receives Federal Pharmaceutical Approval and Registration of NettaVet™ 10% CBD apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
NEW BRUNSWICK, N.J., April 20, 2021 /PRNewswire/ Johnson & Johnson (NYSE: JNJ) (the Company) today announced that the European Medicines Agency s (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) has provided updated guidance for use of the Company s COVID-19 vaccine and confirmed the overall benefit-risk profile remains positive. The guidance follows PRAC review of a small number of cases of a very rare adverse event involving blood clots in combination with low platelet counts that can occur within approximately one to three weeks following injection with the Company s COVID-19 vaccine.
As a result, Johnson & Johnson will update its COVID-19 vaccine Summary of Product Characteristics and Package Leaflet to include important information on the diagnosis and management of this very rare adverse event. Healthcare professionals will be alerted to the signs and symptoms of thromboembolism with thrombocytopenia, as well as the appropri
Johnson & Johnson COVID-19 Vaccine Roll-out to Resume in Europe Following European Medicines Agency (EMA) Review biospace.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biospace.com Daily Mail and Mail on Sunday newspapers.
Trilogy Metals Provides Update on Access Road
News provided by
Share this article
VANCOUVER, BC, April 19, 2021 /PRNewswire/ -
Trilogy Metals Inc. (TSX: TMQ) (NYSE American: TMQ) ( Trilogy or the Company ) is pleased to announce that the Alaska Industrial Development and Export Authority ( AIDEA ) has formally approved the proposed plan and budget for the 2021 summer field season activities and services of up to $13 million for the Ambler Access Project ( AAP ). The cost will be shared 50/50 by AIDEA and Ambler Metals LLC ( Ambler Metals ), the joint venture operating company equally owned by Trilogy and South32 Limited (ASX: S32) (LSE: S32) (JSE: S32) (ADR: SOUHY) ( South32 ).